Cassava Sciences Appoints Three New Members to its Board of Directors
07 déc. 2023 16h01 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of...
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
07 nov. 2023 09h01 HE
|
Cassava Sciences, Inc.
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected...
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
06 nov. 2023 09h15 HE
|
Cassava Sciences, Inc.
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end...
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
25 oct. 2023 09h15 HE
|
Cassava Sciences, Inc.
Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. ...
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
12 oct. 2023 23h43 HE
|
Cassava Sciences, Inc.
CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal record-keeping...
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
05 oct. 2023 09h15 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi...
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
02 oct. 2023 09h00 HE
|
Cassava Sciences, Inc.
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately...
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
18 sept. 2023 09h15 HE
|
Cassava Sciences, Inc.
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials...
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
13 sept. 2023 17h20 HE
|
Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
11 sept. 2023 09h10 HE
|
Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...